Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of STN1010905 Ophthalmic Suspension in Meibomian Gland Dysfunction
jRCT2031240171Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MS-R001 in meibomian gland dysfunction (MGD) (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Evaluation of meibomian gland by IDRA. Started Jul 2024; status: completed.
02
Drugs
MS-R001
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on jRCT2031240171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240171.